Table 4.
Clinical outcomes associated with thyroid hormone treatment, stratified by thyroid stimulating hormone (TSH) concentration
| Adverse outcomes* | Odds ratio (95% CI)† | P value for Interaction | |
|---|---|---|---|
| TSH 2.5-4.0 mIU/L | TSH 4.1-10.0 mIU/L | ||
| Pregnancy loss‡ | 0.91 (0.65 to 1.23) | 0.45 (0.30 to 0.65) | <0.01 |
| Preterm delivery | 1.90 (1.26 to 2.86) | 1.37 (0.82 to 2.29) | 0.33 |
| Preterm labor | 1.25 (0.91 to 1.72) | 1.01 (0.71 to 1.43) | 0.37 |
| Premature rupture of membranes | 1.03 (0.61 to 1.75) | 0.88 (0.53 to 1.46) | 0.67 |
| Placental abruption | 1.42 (0.49 to 4.07) | 2.16 (0.36 to 13.03) | 0.69 |
| Gestational diabetes | 1.40 (0.99 to 1.99) | 1.48 (1.00 to 2.18) | 0.85 |
| Gestational hypertension§ | 1.76 (1.13 to 2.74) | 0.86 (0.51 to 1.45) | 0.04 |
| Pre-eclampsia§ | 1.75 (1.08 to 2.84) | 1.61 (0.91 to 2.88) | 0.83 |
| Poor fetal growth | 0.96 (0.63 to 1.45) | 1.10 (0.74 to 1.63) | 0.65 |
| Tachycardia | 1.61 (0.84 to 3.09) | 1.46 (0.51 to 4.21) | 0.88 |
*Adjusted for age, ethnicity, income, Charlson index, hypertension, obesity, and history of thyroid disease.
†Reference group is untreated women.
‡Additionally adjusted for history of pregnancy loss.
§Adjusted for age, ethnicity, income, Charlson index, obesity, and history of thyroid disease.